Summary of the Conference Call Company and Industry Involved - The conference call involved Huaren Pharmaceutical and its strategic discussion with investors [1] Core Points and Arguments - The meeting was hosted by the chief of the Huaren Pharmaceutical team, Mr. Tan Guochao [1] - The session included a presentation from company leadership, specifically Mr. Zhang, to engage with investors [1] - The discussion was structured into two main parts: company introduction and a Q&A session [1] Other Important but Possibly Overlooked Content - The call served as a follow-up to a previous exchange with Ling Pharmaceutical, indicating ongoing communication and collaboration within the industry [1]

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于石家庄以岭药业股份有限公司 2023 年年度股东大会的 法律意见书 国枫律股字[2024]A0297 号 致：石家庄以岭药业股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2023 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》、《律师 事务所从事证券法律业务管理办法》（以下简称"《证券法律业务管理办法》"）、《律 师事务所证券法律业务执业规则（试行）》（以下简称"《证券法律业务执业规则》"） 等相关法律、行政法规、规章、规范性文件及《石家庄以岭药业股份有限公司章程》（以 下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、出席 会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具 ...

中国国际金融股份有限公司 关于石家庄以岭药业股份有限公司 《关于 2023 年度募集资金存放与使用情况 的专项报告》的 核查意见 保荐机构 1 原中信银行股份有限公司石家庄休门街支行 | | | 二〇二四年四月 中国国际金融股份有限公司（以下简称"中金公司"）作为石家庄以岭药业股 份有限公司（以下简称"以岭药业"或"公司"）的保荐机构，根据《证券发行上市 保荐业务管理办法》《深圳证券交易所股票上市规则》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》及《深圳证券交易所上市公司 自律监管指引第 13 号——保荐业务》等有关法律法规的要求，对以岭药业 2023 年度《石家庄以岭药业股份有限公司关于 2023 年度募集资金存放与使用情况的 专项报告》进行了核查，并出具本核查意见（以下简称"本意见"或"本核查意见"）。 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 公司经中国证券监督管理委员会《关于核准石家庄以岭药业股份有限公司非 公开发行股票的批复》（证监许可[2017] 81 号）核准，公司采用向特定投资者非 公开发行的方式发行每股面值为人民币 1.00 元的普通股股票 74, ...

石家庄以岭药业股份有限公司 证券代码：002603 证券简称：以岭药业 公告编号：2024-012 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会没有涉及变更前次股东大会决议。 一、会议召开和出席情况 （一）会议召开情况： 1、会议召开时间： （1）现场会议时间：2024 年 5 月 22 日下午 14:30 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 （2）网络投票时间：2024 年 5 月 22 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2024 年 5 月 22 日上午 9:15—9:25，9:30—11:30，下 午 13:00—15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2024 年 5 月 22 日 9:15 至 15:00 的任意时间 2、会议地点：石家庄高新区天山大街 238 号以岭健康城会议室 3、会议召开方式：现场投票、网络投票相结合 4、会议召集人和主持人：公司董事会。董事长吴相君先生主持会议。 本次会议的召集、召开程序及表决方式符合有关法律、 ...

Summary of the Conference Call Company Overview - The conference call was hosted by the team from Huaren Pharmaceutical, led by Chief Pan Guochao, focusing on the listed company Yili Pharmaceutical [1] - The meeting included a discussion with company leadership, specifically Mr. Zhang, to provide insights into the company [1] Key Points and Arguments - The call was structured into two main parts: a company introduction and a Q&A session [1] Other Important Content - The event was described as a live strategy meeting held in conjunction with a camping event, indicating a unique approach to investor engagement [1]

Summary of the Conference Call Company and Industry Involved - The conference call involved Huazhong Medicine and its subsidiary Yili Pharmaceutical, focusing on the pharmaceutical industry [1] Core Points and Arguments - The meeting was hosted by the chief of the Huazhong Medicine team, Mr. Tan Guochao, and included a presentation from the leadership of Yili Pharmaceutical, represented by Mr. Zhang [1] - The discussion was structured into two main parts: a company introduction and a Q&A session [1] Other Important but Possibly Overlooked Content - The event was characterized as a summer on-site strategy meeting, indicating a focus on strategic planning and investor engagement [1]

Group 1: Financial Performance - The company's revenue and net profit for 2023 decreased by 7.67% and 42.76% respectively, primarily due to a significant decline in sales of the Lianhua Qingwen product and increased costs of traditional Chinese medicine materials [6][8]. - The company reported other income of 1.8 billion with a growth rate of 69% in the previous year [2]. - The company plans to maintain a stable gross profit margin through cost reduction and efficiency improvement measures [2][6]. Group 2: Market Strategy - The company aims to enhance its retail channel strategy by establishing a dedicated sales team for retail terminals and implementing a combination marketing strategy [2][3]. - The market share of the company's innovative patent Chinese medicines, including Tongxinluo Capsule, Shenmai Injection, and Qiliqiangxin Capsule, increased from 13.64% in 2015 to 16.39% in the first half of 2023 [10]. - The company is focusing on expanding its product line and entering new treatment areas to seize long-term development opportunities in the industry [9]. Group 3: Research and Development - The company has established a national key laboratory for the innovation and transformation of the Luo disease theory, which has led to the development of 14 innovative patent Chinese medicines [3][9]. - The company has completed the filing of 246 national standard Chinese medicine formula granules and 333 provincial standard formula granules, with a high rate of compliance in various provinces [12]. - The company is actively pursuing internationalization by enhancing the brand influence of traditional Chinese medicine and establishing over 130 professional committees abroad [3]. Group 4: Investor Relations - The company has no current plans for stock repurchase, citing various market factors affecting stock prices [4][9]. - The actual controller's stock pledge is low and poses no risk to the company's control or operations [9][11]. - The company emphasizes the importance of cash dividends as a way to return value to shareholders, aligning with long-term sustainable development [13].

Investment Rating - The investment rating for the company is "Outperform the Market" [1] Core Views - The company reported a revenue of 10.318 billion yuan in 2023, a decrease of 17.67% year-on-year, and a net profit of 1.352 billion yuan, down 42.76% [4][6] - The decline in revenue is attributed to decreased market demand for respiratory products due to high inventory levels and a high base from the previous year [4] - Despite the decline in respiratory products, other patented products, particularly in cardiovascular and other categories, showed stable growth [5][6] - The company has invested 935 million yuan in R&D, focusing on new drug development and secondary development of existing products [5][6] Financial Summary - Revenue for 2023 was 10.318 billion yuan, with a projected increase to 10.923 billion yuan in 2024, representing a year-on-year growth of 5.9% [6][9] - Net profit is expected to recover to 1.512 billion yuan in 2024, reflecting an 11.8% increase from 2023 [6][9] - The company’s gross margin for 2023 was 57.3%, with a slight decrease projected to 56.9% in 2024 [6][9] Product Performance - Revenue from respiratory products in 2023 was 3.305 billion yuan, a significant decline of 51.90% [5][6] - Cardiovascular products generated 4.709 billion yuan in revenue, marking a growth of 12.71% [5][6] - Other patented products saw a revenue increase of 69.72%, totaling 1.869 billion yuan [5][6] R&D and Future Prospects - The company has multiple new drugs in various stages of clinical trials, with significant focus on traditional Chinese medicine [5][6] - The forecast for net profit from 2024 to 2026 is 1.512 billion yuan, 1.796 billion yuan, and 2.130 billion yuan, respectively, indicating a positive growth trajectory [6][9] - The company is expected to maintain a unique product layout in the cardiovascular and respiratory fields, supported by ongoing R&D efforts [5][6]

证券代码：002603 证券简称：以岭药业 公告编号：2024-011 公司2023年度已按照15%的企业所得税税率进行纳税申报及预缴，因此本 次取得高新技术企业证书不影响公司2023年度的相关财务数据。 石家庄以岭药业股份有限公司 关于通过高新技术企业重新认定的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 石家庄以岭药业股份有限公司（以下简称"公司"） 于近日收到由河北省科 学技术厅、河北省财政厅、国家税务总局河北省税务局联合颁发的《高新技术 企业证书》（证书编号GR202313003850，发证时间为2023年12月4日，有效期 三年）。 根据相关规定，公司自获得高新技术企业认定后将连续三年享受国家关于 高新技术企业的相关优惠政策，按15%税率缴纳企业所得税。 特此公告。 石家庄以岭药业股份有限公司 董事会 2024 年 5 月 11 日 ...

Investment Rating - The investment rating for the company is to maintain attention due to its position as a leader in traditional Chinese medicine innovation [4]. Core Views - The company reported a revenue of 10.318 billion yuan in 2023, a year-over-year decrease of 17.67%, and a net profit attributable to shareholders of 1.352 billion yuan, down 42.76% year-over-year [2]. - The respiratory product line faced significant declines due to high inventory levels and a high base effect from 2022, while non-respiratory products showed steady growth [2][3]. - The company continues to invest in innovative traditional Chinese medicine research, with a total R&D expenditure of 935 million yuan in 2023, representing 9.06% of revenue [3]. Financial Summary - Revenue projections for 2024-2026 are 11.386 billion yuan, 12.541 billion yuan, and 13.717 billion yuan, with corresponding growth rates of 10.35%, 10.14%, and 9.38% [4]. - Net profit forecasts for the same period are 1.532 billion yuan, 1.759 billion yuan, and 1.990 billion yuan, with growth rates of 13.27%, 14.83%, and 13.10% [4]. - The company’s earnings per share (EPS) are projected to be 0.92 yuan, 1.05 yuan, and 1.19 yuan, with price-to-earnings (P/E) ratios of 21, 18, and 16 respectively [4][5].